CD34 and myelodysplastic syndrome: We transplanted MISTRG mice with IDH2R140Q-mutant MDS-EB-2 CD34+ cells (Y021, Supplementary Table 1) and treated engrafted mice with either vehicle or enasidenib via oral gavage for 30 days.